CTLA4 and metastatic melanoma: Data from the Sharma laboratory in both preclinical models as well as patients with bladder cancer, prostate cancer, and metastatic melanoma suggested that increased ICOS protein expression on CD4+ T cells was indicative of a response to CTLA-4 treatment10,36–39.